Welcome to our dedicated page for Virios Therapeutics SEC filings (Ticker: VIRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VIRI SEC filings page on Stock Titan serves as an access point to the regulatory history of Virios Therapeutics, Inc. and its successor, Dogwood Therapeutics, Inc. Virios Therapeutics previously reported as a development-stage biotechnology company focused on antiviral combination therapies for fibromyalgia and Long-COVID, while later filings under the Dogwood Therapeutics, Inc. name reflect the combined entity following its business Combination with Wex Pharmaceuticals, Inc.
Through this page, users can review Form 8-K current reports that document material events in the company’s transition. For example, an October 2024 press release, referenced in subsequent disclosures, describes the Combination and the change of the corporate name to Dogwood Therapeutics, Inc., along with the shift in Nasdaq trading from the VIRI ticker to DWTX. Later Form 8-K filings filed as Dogwood Therapeutics, Inc. detail matters such as equity incentive plan amendments, annual meeting results and executive compensation adjustments, illustrating the continuity of the registrant under a new name.
Stock Titan enhances these filings with AI-powered summaries that aim to clarify the key points of each document, helping readers quickly understand topics such as corporate governance changes, equity plan share increases or the announcement of quarterly results. Real-time updates from EDGAR mean that new 8-Ks and other forms appear on this page as they are filed, while historical filings remain available for users who want to study the evolution from Virios Therapeutics to Dogwood Therapeutics.
For investors analyzing the former VIRI symbol, this filings archive provides a structured view of how Virios Therapeutics’ antiviral programs and corporate structure were incorporated into Dogwood Therapeutics, Inc., and how the combined company continues to report under the same Commission file number with a new trading symbol.
Dogwood Therapeutics is a pre-revenue biopharmaceutical company focused on its Na v 1.7 program Halneuron and antiviral combinations; after the October 2024 Combination the company reports total assets of $96.7M including capitalized IPR&D of $69.3M and goodwill of $12.46M. Cash totaled $13.40M at June 30, 2025 and net cash used in operating activities was $8.71M for the six months.
Dogwood recorded net losses of $3.81M for the quarter and $14.73M year-to-date, producing an accumulated deficit of $88.55M and basic/diluted net loss per common share of $(1.99) (quarter) and $(9.51) (six months). The company completed a registered direct offering (net proceeds ~$4.25M) and converted related-party debt into Series A-1 preferred (debt extinguishment of ~$19.9M with a recognized loss of $6.13M). Management discloses substantial doubt about the company’s ability to continue without additional financing beyond the first quarter of 2026.
Dogwood Therapeutics, Inc. furnished a press release reporting its results of operations for the quarter ended June 30, 2025, which is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 of this Current Report.
The Form notes the information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings. The registrant identifies as an emerging growth company and did not check the box indicating an election to forgo the extended transition period. The company’s common stock trades on the Nasdaq Capital Market under ticker DWTX. The report is signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.
FAQ
What is the current stock price of Virios Therapeutics (VIRI)?
What is the market cap of Virios Therapeutics (VIRI)?
